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Current gold standard therapeutic strategies for T2DM target insulin resistance or β cell dysfunction as their core
mechanisms of action. However, the use of traditional anti-diabetic drugs, in most cases, does not significantly
reduce macrovascular morbidity and mortality. Among emerging anti-diabetic candidates, glucagon like peptide-1
(GLP-1) based therapies carry special cardiovascular implications, exerting both direct as well as indirect effects.
The direct cardiovascular effects of GLP-1 and its analogs remain the focus of this review.Article
Cardiovascular disorders (CVDs) are the leading cause of
adult mortality and morbidity worldwide, accounting for
17 million deaths (30% of all deaths) in 2008 [1]. CVDs
pose a significant economic burden on the healthcare
systems of both developing and developed countries.
According to an estimate by the American Heart Asso-
ciation (AHA), the annual US medical costs for cardiovas-
cular diseases are likely to increase to over USD 800
billion in 2030, which is nearly triple the amount spent in
2010 (USD 272 billion) [2]. Risk factors of CVDs, which
are grouped into modifiable and non-modifiable, include
hypertension, smoking, hyperlipidemia, being overweight
and having a sedentary lifestyle. Most of these risk factors
overlap with those of type 2 diabetes mellitus (T2DM)
and past studies have demonstrated such a strong rela-
tionship between these two entities that AHA has
declared “diabetes is a cardiovascular disease” [3].
Recent advancements in healthcare have witnessed an
improvement in the prognosis of T2DM patients due to
earlier detection and improvements in diabetes care [4].
However, the rationale of intensive anti-diabetic therapy
has been challenged in multiple studies. The ACCORD
study was conducted on patients with T2DM having
HbA1c concentrations >7 · 5% and established cardio-
vascular disease or ≥2 cardiovascular risk factors in
order to determine whether a more intensive thera-
peutic strategy was associated with a reduction in theCorrespondence: asfandyarsheikh@gmail.com
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reproduction in any medium, provided the orrate of cardiovascular events [5]. The study, which
ended prematurely due to a higher mortality rate in the
intensive treatment group, failed to report significant
reduction in major cardiovascular events, giving a no-
tion that intensive therapy was associated with signifi-
cant harm in high risk patients [6].
Current gold standard therapeutic strategies for T2DM
target insulin resistance or β cell dysfunction as their core
mechanisms of action. For instance, biguanides and thia-
zolidinediones, also called “sensitizers”, act by reducing
hepatic glucose output and promoting uptake of glucose
by the periphery. Similarly, another class of drugs, called
“secretagogues”, acts by triggering insulin release from the
pancreatic β cells. However, the use of traditional anti-
diabetic drugs, in most cases, does not significantly reduce
macrovascular morbidity and mortality. This notion has
led researchers into searching for alternatives that provide
substantial benefits without the added side effects. This
idea is especially significant because of the fact that
T2DM and cardiovascular diseases are almost invariably
related. Among emerging anti-diabetic candidates, gluca-
gon like peptide-1 (GLP-1) based therapies carry special
cardiovascular implications (Figure 1).
The incretin effect
It is a well-known fact that oral administration of glu-
cose is a more potent stimulus for insulin secretion than
parenteral infusion [8]. This notion implies the presence
of an accessory secretory stimulus from the gastrointes-
tinal tract, unrelated to blood glucose levels. The term
“incretin effect” refers to a concept which postulates that
a family of endocrine factors is responsible for inducinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Cardiometabolic actions of GLP-1 and GLP-1 agonists [7].
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[9]. However, the term is somewhat vague, given the fact
that incretins have been increasingly reported to have
certain non-glucose-lowering functions such as the expan-
sion and preservation of pancreatic β cell mass, bone me-
tabolism, neuroprotection and cardioprotection [10,11].
The main hormones in the group include glucose-
dependent insulinotropic polypeptide (GIP) and glucagon-
like peptide-1 (GLP-1). GIP is a 42 amino-acid peptide
hormone released from the K cells of the proximal intes-
tine. Although the main action of GIP is to provide a
stimulus for the release of insulin after an oral glucose
challenge, the hormone has also been reported to promotelipid uptake in adipocytes [12]. GIP has also been found to
exert influence over other tissues such as bone, although
its extraglycemic profile is quite limited and largely pre-
clinical in nature compared to its much celebrated partner
GLP-1 [13].
GLP-1 is a derivative of the transcription product of
proglucagon gene and is synthesized mainly by the
L cells of ileal mucosa. The full length N-terminal ex-
tended forms of GLP-1 (1–37 and 1–36) are biologically
inert. However, removal of the first 6 amino acids yields
shorter compounds (7–37 and 7–36) that have enhanced
biological activity [14]. Further cleavage of the first two
N-terminal amino acids results in the formation of GLP-
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GLP-1 is released in response to ingestion of nutrients
and acts on pancreatic β cells to stimulate insulin secre-
tion. Both have short half-lives because of rapid enzymatic
inactivation mainly by dipeptidyl peptidase-4 (DPP-4).
However, unlike GIP, GLP-1 has not been found to have a
direct role in fat deposition in adipose tissues [16].
Furthermore, while GIP augments postprandial glucagon
response, GLP-1 extenuates it [17-19]. Similarly, GIP pro-
motes bone formation while GLP-1 inhibits it [20]. Both
GIP receptor (GIPR) and GLP-1 receptor (GLP1R) belong
to the G-protein coupled receptor family that function by
activating adenylate cyclase causing increased levels of
intracellular cyclic adenosine monophosphate (cAMP)
and activation of protein kinase A (PKA) [21]. Both have
been found to be associated with improved cognitive func-
tion due to their expression in brain tissue [22-24]. How-
ever, unlike GIPR, GLP-1R are present in several other
tissues such as peripheral nervous system, lung and heart
(Figure 2) [19].
GLP-1 based anti-diabetic therapies may be divided
into two main groups: GLP-1 agonists and DPP-4Figure 2 Mechanism of action of GLP-1 [25].inhibitors (Figure 3). Exenatide and liraglutide, which
belong to the first category, have already been approved
by the FDA for the treatment of T2DM. These drugs are
homologous (53% and 97% respectively) to natural GLP-1,
with the added benefit of resistance to degradation by
DPP-4 which enhances their half-life. Sitagliptin, vil-
dagliptin, saxagliptin and linagliptin (DPP-4 inhibitors)
have also been FDA approved, while others are under-
going trials [26]. The prospects for these drugs are quite
exciting, especially for those with superimposed CVDs,
given the fact that these drugs provide an added advan-
tage of cardioprotection via different yet intricately
related mechanisms.
Direct cardiovascular effects of GLP-1
Previous researches have demonstrated the presence of
high-affinity receptors for GLP-1 in both human and
animal models of hearts and vascular tissues, although
the receptors were not localized until later by Ban et al.
to cardiomyocytes, endothelium, and vascular smooth
muscle cells [28-31]. The presence of these receptors
suggests the possibility of prospective drug targets for
Figure 3 Cardiovascular effects of DPP-4 inhibitors [27].
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absence of pre-existing T2DM.
Effects on myocardium
Electrophysiologic effects
GLP-1 infusions in murine models have been reported
to cause a dose-dependent inotropic and chronotropic
effect. However, the existence of direct effects on cardio-
vascular system remains controversial due to conflicting
results for in vivo and in vitro studies. For example,
Barragan et al. and Yamamoto et al. demonstrated
sympathomimetic mechanisms to be responsible for ino-
tropic and chronotropic effects in murine models
in vivo, and others such as Ahren et al. demonstrated
similar effects that were not suppressed by reserpine,
propranolol, or phentolamine, thereby suggesting a
direct mode of action [32-34]. These findings was fur-
ther supported by the study of Gros et al. who demon-
strated a diminished basal heart rate and diastolic
dysfunction after insulin administration in GLP-1R
knockout mice [35]. However, experiments conducted in
other settings have yielded contradictory results. For
example, Deacon et al. failed to demonstrate similar
effects in pig models while Vila Petroff et al. reported
negative inotropic effects in rat myocyte cultures [36,37].
Similarly, cardiovascular benefits independent of GLP-
1R activation have also been demonstrated [38].Findings from human trials have demonstrated only a
modest effect of GLP-1 analog administration on heart
rate. In a placebo-controlled trial conducted on subjects
with T2DM already receiving anti-diabetic therapy,
exenatide administered subcutaneously demonstrated no
clinically significant effects on heart rate [39]. Exenatide
and liraglutide have been found to have no significant
effect on QT interval in trials using moxifloxacin as a
positive control [40]. Similar effects have been noted with
DPP-4 inhibitors such as sitagliptin and vildagliptin,
whereby supratherapeutic doses have succeeded in produ-
cing only a minor increase in the QT intervals [41,42].
The effects of GLP-1 infusion have also been studied on
animal models of arrhythmias. Dokken et al. observed an
amelioration of coronary flow reserve on administration
of GLP-1 in pigs with a few minutes of untreated ventri-
cular fibrillation followed by resuscitation [43]. However,
no significant improvement was found in myocardial
function [43]. Similar findings were reported by who
attributed the improvement in coronary function to
reduced markers for reactive oxygen species [44]. Human
studies on the potential uses are scarce. A study
conducted on patients scheduled to undergo coronary
artery bypass graft demonstrated reduced occurrence of
arrhythmias in those infused with GLP-1 compared with
controls [45]. A patent has been registered for treatment
of arrhythmias with GLP-1 agonists [46].
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Various theories have been put forward to explain the
protective effects of GLP-1 on myocardium. The most
upheld revolves around cardiac metabolism [47]. Under
normal physiological conditions, cardiomyocytes utilize
fatty acids as a fuel for energy [48]. During acute ische-
mia, they switch to carbohydrate metabolism, which
eventually leads to insulin resistance [48]. GLP-1 ana-
logs, such as liraglutide, have been shown to ameliorate
insulin resistance and inflammation in previous studies
[49]. This attenuation of insulin resistance, therefore,
plays a favorable role in cardioprotection [50]. Another
proposed mechanism that involves improved glucose
uptake is related to the increase in glucose transport
proteins (GLUT-2 and GLUT-4) by GLP-1 [51]. In
patients with T2DM, GLUT-4 expression is markedly
reduced, and GLP-1 mediated up-regulation of GLUTs,
especially in cardiomyocytes, helps preserve their integ-
rity [52]. GLP-1 has also been demonstrated to decrease
lactate and pyruvate concentrations, thereby providing
another mechanism for cardioprotection via improve-
ment in metabolism [53].
Anti-apoptotic mechanisms have also been proposed.
The first mechanism involves activation of cAMP and
PI-3 K pathways via GLP-1R [54]. Bose et al. demon-
strated a reduction in infarct size on administration of
GLP-1 both in vitro and in vivo. This effect was abro-
gated in the hearts in vitro by GLP-1 receptor anta-
gonist, cAMP inhibitor and PI-3 K inhibitor [55]. Other
pathways and mediators have also been demonstrated to
play a role. For example, Bose et al. demonstrated inhi-
bition of GLP-1 mediated cardioprotection after admin-
istration of rapamycin, suggesting a role of mTOR/p70s6
kinase pathway. In an experimental study conducted by
Noyan-Ashraf and colleagues, Liraglutide upregulated
the independent expression of cardioprotective genes,
including Akt, PPARβ-δ, Nrf-2, and HO-1, while sup-
pressing the expression of GSK3β and activation of
caspase-3 in murine hearts [56]. This effect was also
found to be superior to metformin’s in diabetic mice
hearts [56]. Exenatide, another GLP-1 analog, has also
been shown to provide cardioprotection via similar
mechanisms [57]. Timmers et al. reported reduction in
myocardial infarct size and prevention of deteriorated
cardiac function on exanatide treatment in porcine
model of ischemia/reperfusion [58]. This was associated
with an increase in phosphorylated Akt and Bcl-2
expression as well as superoxide dismutase and catalase
activity, and a decrease in active caspase 3 expression.
Serum insulin levels were also increased without a corre-
sponding change in glucose levels. The cardioprotective
function of exendin-4 during hyperglycemic states was
further elaborated in a recent study conducted by
Younce, whereby exendin-4 was found to improvecardiac function by inhibiting thapsigargin-mediated
decrease in SERCA2a mRNA and via active phosphory-
lation of phospholamban [59]. Sitagliptin and vildagliptin
have also been shown to reduce infarct size in various
animal studies [60-62]. Anti-inflammatory mechanisms
via attenuation of neutrophil activation were demon-
strated by Dokken et al. in a rodent ischemia-reperfusion
model, who reported a reduced expression of CD11b in
rats receiving GLP-1 therapy [63].
Human studies have also provided evidence for cardio-
protective functions of GLP-1 analogs and DPP-4 inhi-
bitors in both diabetics and non-diabetics, although
larger, randomized trials are still required. In the EXAMI
study, Bernink et al. demonstrated that although high
dose exenatide treatment did not exercise a significant
effect on left ventricular function or area at risk, a trend
was observed towards a smaller infarct size as percen-
tage of the area at risk in patients with first acute myo-
cardial infarction who were to be treated with primary
percutaneous coronary intervention [64]. Lonborg and
colleagues demonstrated a reduction in infarct size and
increased myocardial salvage on exenatide administra-
tion in a randomized, placebo-controlled trial in human
subjects with ST elevation myocardial infarction under-
going primary percutaneous coronary intervention [65].
Improvements in regional and global left ventricular
function were observed by Nikolaidis et al. in human
subjects with acute myocardial infarction infused with
native recombinant GLP-1 for 72 hours following angio-
plasty [66]. These effects were independent of location
of infarct or diabetic status of the patients [66]. Similar
effects were demonstrated by investigators, both before
and after revascularization procedures [67,68]. In a
retrospective analysis of the IMS LifeLink™ database
conducted by Best et al., patients on exenatide were less
likely to have a major cardiovascular event, and had
reduced risk of hospitalization compared with those
receiving other anti-diabetics [69].
DPP-4 inhibitors have also shown encouraging results
in human studies. In a placebo-controlled trial conducted
on patients having pre-existing coronary artery disease
with preserved left ventricular function, increase in GLP-1
levels caused by DPP-4 inhibition resulted in improve-
ment of global and regional left ventricular function and
amelioration of post-ischemic stunning [70]. New hori-
zons are being explored in this regard, with a recent study
providing promising results in the combination trial
(SITAGRAMI-Trial) of sitagliptin and G-CSF based stem
cell mobilization [71].
Cardioprotective functions in heart failure
Both preclinical and clinical studies have demonstrated
beneficial effects of GLP-1 on the failing heart. Most of
these studies identify attenuation of insulin resistance as
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lished in 2004, Nikolaidis et al. demonstrated improve-
ment of cardiac output, systolic/diastolic function and
other hemodynamic parameters after infusion of recom-
binant GLP-1 in canine models of pacing-induced di-
lated cardiomyopathy [50]. These results were further
supported by another study from the same lab, whereby
GLP-1 was shown to stimulate myocardial glucose up-
take via mechanisms that were p38α MAP kinase and
NO dependent, but independent of adenylyl cyclase or
Akt [73]. These results have been successfully replicated
in studies using other animal models. Vyas et al. re-
ported improved glucose tolerance, cardiac contractility,
and survival after infusion of exenatide in murine model
of dilated cardiomyopathy [52]. Although the expression
of myocardial GLUT4 was upregulated, no significant
differences were found in the total myocardial GLUT1
levels between groups [52]. Another important finding
of this study was that exenatide was also found to abol-
ish the harmful effects of ritonavir (GLUT4 antagonist)
on survival [52]. Poornima et al. demonstrated greater
survival, preserved LV function, decreased myocyte
apoptosis and reduced caspase-3 activation on chronic
GLP-1 infusion in spontaneously hypertensive, heart
failure prone rats [74]. Additionally, increased plasma
insulin, decreased triglycerides, and improved myocar-
dial glucose uptake were observed in the GLP-1 treated
group [74]. Similar results were reported by Liu and
colleagues [75].
DPP-4 inhibition has also yielded positive results. For
example, Shigeta et al. observed reversal of diastolic
ventricular dysfunction in a rat model due DPP4 inhi-
bition, via local actions on angiogenesis and inotropic ef-
fects [76]. Similar results were reported by Gomez et al.
who observed preservation of glomerular filtration rate,
increase in stroke volume, and enhancement of the ino-
tropic effect of exogenous brain natriuretic peptide due
to DPP-4 inhibition [77].
Earlier studies have hinted towards improved myo-
cardial function with reasonable tolerability in heart
failure patients infused with GLP-1 [78]. For example,
Sokos et al. reported improved left ventricular ejection
fraction, myocardial ventilation oxygen consumption,
6-minute walk distance and quality of life in both dia-
betic and non-diabetic, class II/IV heart failure patients
infused with GLP-1 [79]. However, Halbirk et al.
reported only minor cardiovascular effects despite
increased insulin levels and reduced plasma glucose con-
centration, in patients without diabetes but with com-
pensated heart failure [80]. Similarly, in another study
conducted by Nathanson et al., infusion of exenatide in
male type 2 diabetic patients with chronic heart failure
exhibited positive chronotropism and favorable effects
on the cardiac index and hemodynamics; however, thedefinitive effects of exenatide in such patients were still
inconclusive [81]. This notion implies that, although
favorable results have been reported for clinical studies,
the paucity of existing data warrants the need for further
ventures in order to further elucidate the favorable
effects of GLP-1 in heart failure patients [82].
Effects on vasculature
Vasoprotective actions against endothelial dysfunction and
atherosclerosis
Endothelial dysfunction, characterized by impaired vaso-
motility and an increase in pro-coagulant and pro-
inflammatory mediators, is a key feature of T2DM [83].
The robust relationship between these two entities has
been largely attributed to oxidative stress caused by hyper-
glycemia, although a few studies have failed to demon-
strate a significant reduction in cardiovascular risk as a
result of intense glycemic control [84-86]. A strong asso-
ciation also exists with obesity and insulin resistance [87].
Atherosclerosis is the hardening of arterial wall due to
progressive accumulation of fatty substances. It is
caused by the interplay between endothelial cells, vascu-
lar smooth muscle and macrophages. Since reduced
anti-coagulant properties and increased pro-inflammatory
mediators and reactive oxygen species play important
roles in the development of both endothelial dysfunction
and atherosclerosis, the association between the two is
almost ubiquitous [88].
Newly published reports are improving our under-
standing of the role of GLP-1 and its analogs in the im-
provement of endothelial function. For example, in a
study conducted by Nathanson et al. on rat conduit
arteries ex vivo, exenatide was not found to significantly
ameliorate triglyceride-induced endothelial dysfunction
nor did it exert a potent vasorelaxant effect [89]. How-
ever, contrasting results were found by Goyal et al. who
reported improvement in acetylcholine-induced endo-
thelium relaxation on administration of exendin-4 in rat
model of T2DM [90]. This effect was abolished by an
inhibitor of NOS, suggesting the activation of eNOS by
exendin-4 [90]. These results were again contradicted by
Murthy et al. who found no significant changes in eNOS
and NFkappaB-p65 expression in exenatide treated
non-diabetic rats [91]. However, a more recent study
conducted by Ding et al. on human umbilical vein endo-
thelial cells (HUVEC) has demonstrated upregulation of
eNOS expression via GLP-1R dependent pathways [92].
GLP-1 and its analogs have also been found to inhibit
cellular migration and other essential facets of inflam-
mation, thus mitigating atherosclerosis. Nagashima et al.
observed inhibition of macrophage foam cell formation
by both GLP-1 and GIP, followed by cAMP activation
[93]. These effects were found to be associated with
downregulation of CD36 and ACAT-1 [93]. Similarly,
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sponse in macrophages by Arakawa et al. [94]. Shiraishi
and colleagues demonstrated upregulation of alterna-
tively activated macrophage-related molecules, such as
IL-10, CD163, and CD204 in human monocyte-derived
macrophage by GLP-1 [95]. GLP-1 also activated
STAT3 in a GLP-1R dependent manner [95]. GLP-1 also
exerts influence on inflammatory mediators. For
example, Liu et al. demonstrated inhibition of TNF-α
mediated PAI-1 induction, ICAM-1 and VCAM-1
expression by liraglutide in HUVEC [96]. However, a
recent study by Panjwani et al. has provided contradict-
ory results. Taspoglutide (a long acting GLP-1 agonist)
was not found to have significant anti-atheromatous
effects, although it did reduce hepatic triglyceride levels,
suggesting an indirect mode of action [97]. DPP-4 inhi-
bitors have also been shown to have anti-inflammatory
actions. Recent studies have demonstrated direct suppres-
sion of aortic atherosclerosis by both PKF275-055 and
sitagliptin [98-100].
GLP-1 has been shown to confer protective effects on
the endothelium and to maintain its integrity. For
example, Oeseberg showed that dipeptidyl-peptidase 4
(DPP-4) inhibition significantly reduced vascular senes-
cence in a diabetic rat model. This effect was mediated
via activation of cAMP response element-binding trans-
cription factor in a cAMP/PKA-dependent manner and
induction of oxidative defense genes HO-1 and NQO1
[101]. Similarly, Goto showed that exendin-4 reduced
intimal thickening after vascular injury by the suppres-
sion of platelet-derived growth factor-induced prolifera-
tion in isolated murine, rat and human aortic vascular
smooth muscle cells [102]. In vitro studies in HUVECs
have further demonstrated these effects. In a study by
Ishibashi et al., GLP-1 was shown to dose-dependently
inhibit gene expression for advanced glycation end pro-
ducts receptor (RAGE) in HUVEC via activation of
cyclic AMP pathways and decrease reactive oxygen spe-
cies generation [103]. This effect was directly mediated
via the GLP-1R [103]. In another study, liraglutide was
shown to prevent the onset of endoplasmic reticulum
stress in HUVECs exposed to high glucose via dose
dependent induction of mitochondrial fusion marker,
OPA1, thereby inhibiting mitochondrial fragmentation
and apoptosis [104]. Liu and colleagues showed that
GLP-1 suppressed the oxidized low-density-lipoprotein-
induced apoptosis of MILE SVEN 1 cells by inactivating
the PARP-1/iNOS/NO pathway [105]. This effect was
accompanied by a significant decrease in intracellular
nitric oxide activity, suppression of lipid peroxidation
and restoration of the activities of endogenous antioxi-
dants [105]. Ergogdu showed that incubation of human
coronary artery endothelial cells (HCAECs) with
exendin-4 caused an increase in DNA synthesis and cellproliferation through PKA-PI3K/Akt-eNOS activation
pathways via a GLP-1 receptor-dependent mechanism
[106]. Another paper by the same group showed that
incubation of HCAECs with exendin-4 resulted in a dose-
dependent up-regulation of DNA synthesis which was
associated with enhanced eNOS and Akt expression [106].
This effect was inhibited by PKA, PI3K, Akt or eNOS
inhibitors and abolished by a GLP-1 receptor antagonist.
Human studies have also demonstrated beneficial effects.
For example, Ceriello et al. reported that during the meal,
GLP-1 exerted simultaneous effects on insulin secretion
and endothelial protection, in a manner dependent on the
level of glycemia [107]. Additional data show that
liraglutide reduces several markers of cardiovascular risk,
such as body weight, A1C levels, Systolic BP, C-reactive
protein, type 2 natriuretic peptide, and PAI-1 [108,109].
Exenatide has also exhibited similar effects, with efficacy
comparable to that of metformin [110].
Regulation of vasomotor functions and arterial blood
pressure
GLP-1 has been demonstrated to modulate peripheral
arterial blood flow by exerting direct effects or via signals
from the CNS. Richter showed that addition of GLP-1
caused increase in 35S-sulfate-labeled macromolecule
secretion and relaxation of the pulmonary artery [111]. He
concluded that GLP-1 may act as neurotransmitter of the
peptidergic nervous system in airways [111]. Similarly,
Golpon also showed the role of GLP-1 in the modulation
of pulmonary vascular tone [112]. Nystrom and colleagues
showed dose-dependent relaxation of femoral artery rings
by GLP-1 in a rat organ bath model [113]. This effect was
shown to be independent of NO and the endothelium
[113]. In contrast, Dong et al. concluded that GLP-1 had a
role in expanding microvascular volume via a PKA/NO-
dependent pathway in the vascular endothelium [114]. In
another study, GLP-1 and exendin-4 treatment was shown
to normalize the altered vascular tone in type 2 diabetic
rats, with the latter being less effective [115]. In a study
published in 2012, Wu hypothesized that the vascular
modulatory effect on pancreatic islet microcirculation
may in fact be one of the mechanisms for anti-diabetic
actions of GLP-1 and exendin-4. She showed that infusion
of both GLP-1 and exendin-4 prevented glucose-induced
pancreatic blood flow redistribution into the islets, an
effect that was not abolished by blocking NO formation
[116]. Human studies have also pointed towards amelio-
ration of endothelial dysfunction and modulation of vas-
cular reactivity [117]. In the study conducted by Nystrom,
GLP-1 was found to be associated with improvement in
endothelial dysfunction without improvements in insulin
resistance in T2DM patients with coronary heart disease
[118]. Due to the direct and indirect role of GLP-1 on
endothelial functions, GLP-1 receptor antagonists may
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cular risks in T2DM patients [119].
GLP-1 has also been shown to regulate peripheral arte-
rial blood flow via signals from the CNS [33,120]. For
example, in 2004, Cabou et al. demonstrated that central
GLP-1 signaling plays an essential role in the regulation of
arterial blood flow, heart rate, and insulin sensitivity [121].
This study was further reinforced by another one in 2011,
whereby brain GLP-1 signaling was shown to activate
hypothalamic glucose-dependent PKC-δ to regulate fe-
moral artery blood flow and insulin sensitivity [122]. Simi-
larly, Isbil-Buyukcoskun and colleagues showed that
intracerebroventricularly injected GLP-1 had a role in
increasing blood pressure and heart rate [123]. The former
was mediated by stimulation of central nicotinic and
partially muscarinic receptors and vasopressinergic sys-
tem, while the latter was mediated by stimulation of cen-
tral nicotinic receptors [123].
GLP-1 and its analogs also have potent effects on blood
pressure, and may therefore play a role in ameliorating
hypertension. Previously published data has demonstrated
the GLP-1 analogs to have a direct natriuretic effect and a
direct mode of action on endothelial vasodilatation
[124,125]. The mechanisms for GLP-1 mediated diuresis
and natriuresis were explained by Crajoinas et al., who
reported that these effects were mediated by changes in
renal hemodynamics and by downregulation of NHE3
activity in the renal proximal tubule [126]. Recombinant
GLP-1 was shown by Yu et al. to have an antihypertensive
effect in Dahl Sensitive rats fed with a high salt diet, in
addition to cardioprotective and renoprotective effects
[127]. The antihypertensive effect is due to its diuretic and
natriuretic actions, rather than amelioration of insulin
resistance [127]. Exendin-4 also has antihypertensive
effects in salt-sensitive mice models. Hirata and colleagues
demonstrated that exendin-4 attenuated high-salt load
induced hypertension, prevented angiotensin II induced
hypertension and inhibited angiotensin II-induced
phosphorylation of ERK1/2 [128]. Exenatide has also
been shown to have an antihypertensive effect in
glucocorticoid-induced model of the metabolic syn-
drome [129]. This effect occurred independently of
changes in body weight [129]. DPP-4 inhibitors have
also been demonstrated to have an antihypertensive
effect. For example, Sitagliptin was shown to increase
GLP-1 and GLP-1 receptor expression in spontaneously
hypertensive rat renal arteries by Liu [130]. This
upregulation was associated with improvement of
endothelial function via restoration of NO bioavaila-
bility [130]. This effect was further shown to be partially
due to inhibition of NHE3 activity in renal proximal
tubule [131].
GLP-1 and its analogs have also been demonstrated to
have antihypertensive effects in human studies. Forexample, exenatide intake was associated with weight
loss and reduction in levels of HbA1c, systolic blood
pressure, triglycerides, and high-sensitivity CRP in obese
patients with type 2 diabetes on insulin [132]. The effect
on systolic blood pressure was further confirmed by a
pooled analysis of 2171 patients [133]. Liraglutide, long-
acting GLP-1 agonist, has also been shown to induce sig-
nificant weight loss and reduce SBP in a group of Asian
patients [134]. Antihypertensive effects have also been
observed for DPP-4 inhibitors. For example, Yanai et al.
reported reduction of body weight, HbA1c levels and
blood pressure after 6-month treatment with sitagliptin
[135]. The antihypertensive effect of sitagliptin was con-
firmed by Ogawa, who showed that this effect was inde-
pendent of BMI and blood glucose reduction [136].
Conclusion and future directions
Recent studies provide potent evidence for the pleio-
tropic effects of GLP-1 on the cardiovascular system.
This review attempts to highlight the direct cardiovas-
cular effects, without going into details of the indirect
actions, which have already been thoroughly reviewed in
previous papers. Majority of the present GLP-1 based
studies employ GLP-1 analogs such as exenatide as their
primary drugs, which raises a question for their cardio-
vascular safety and contribution to major adverse cardio-
vascular events (MACE). In an integrated analysis of
3,945 participants, Ratner et al. observed no increase in
cardiovascular risk with the use of exenatide BID in
patients with type 2 diabetes [137]. Similarly, liraglutide
has not been found to be associated with an increase in
MACE in FDA’s review as well as in a pooled analysis of
phase 2 and 3 clinical trials [138,139]. Its safety has been
confirmed by a recent study published in Lancet,
whereby liraglutide had an efficacy comparable to that of
glimepiride, but was associated with fewer cardiovascular
events [140]. DPP-4 inhibitors also have a favorable car-
diovascular safety profile [141]. However, the recently
concluded SAVOR-TIMI 53 trial conducted on patients
with T2DM with either a history of established CVD or
multiple CVD risk factors, has failed to demonstrate the
superiority of saxagliptin over placebo in reducing a
composite end point of cardiovascular death, nonfatal
MI or nonfatal ischemic stroke when added to usual care
[142,143]. Nevertheless, the relatively low occurrence of
MACE implies that the translation of ongoing research
to the bedside would provide a safe therapeutic alter-
native to available anti-diabetics, with additional cardio-
protective and vasculoprotective effects.
It is important to note that the dividing line between
direct and indirect effects is tenuous and somewhat
vague. Its fragility is reinforced by the relative scarcity of
existing data that provides conclusive evidence for
delineating the two. This notion implies the need for
Sheikh Diabetology & Metabolic Syndrome 2013, 5:47 Page 9 of 13
http://www.dmsjournal.com/content/5/1/47additional preclinical and clinical studies that are
focused primarily on distinguishing these two entities.
These studies will not only provide therapeutic benefits
to T2DM patients with superimposed CVDs, but may
also unveil new horizons in cardiovascular research. A
search at http://www.clinicaltrials.gov (using keywords
GLP-1 and cardiovascular) returns 36 open studies,
which hints towards an increasing interest in the cardio-
vascular effects of incretin based therapies.
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